MetaCap

Immatics N.V. (IMTX) vs Solid Biosciences (SLDB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Solid Biosciences (SLDB) has outperformed Immatics N.V. (IMTX) over the past year, gaining 33.0% versus a loss of 43.4%. Over five years, IMTX leads with a -48.6% price change compared with -77.8% for SLDB. Immatics N.V. is the larger company by market cap ($878.6 million vs $697.6 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMTX-43.43%SLDB+32.98%
+146%+47%-52%
Nov 21, 20251 yearNov 20, 2026
IMTX-51.47%SLDB-79.06%
+18%-40%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMTX versus SLDB key metrics
MetricIMTXSLDB
Share price$5.77$6.25
Market cap$878.58M$697.57M
1-day change-3.03%-2.95%
YTD return-45.05%+10.82%
1-year return-43.43%+32.98%
5-year return-48.57%-77.78%
EPS (TTM)$-1.95$-1.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-174.32M
52-week high$12.41$11.45
52-week low$5.72$4.65
Distance from 52-week high-53.51%-45.41%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+176.78%+199.36%
Average volume962.74K1.30M
Shares outstanding152.27M111.61M
Employees721121
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SLDB has outperformed IMTX by 76.4 percentage points over the past year.

About Immatics N.V.

IMTX stock →

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees

About Solid Biosciences

SLDB stock →

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees

IMTX vs SLDB FAQ

Which is bigger, Immatics N.V. or Solid Biosciences?

Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $697.57M for Solid Biosciences (SLDB).

Which stock has performed better over the past year, IMTX or SLDB?

SLDB returned +32.98% over the past 12 months, compared with -43.43% for IMTX (price return, excluding dividends). Past performance does not predict future results.

Are Immatics N.V. and Solid Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons